Klare, H; Neudörfl, JM; Brandt, SD; Mischler, E; Meier-Giebing, S; Deluweit, K; Westphal, F; Laussmann, T. Analysis of six “neuro-enhancing” phenidate analogs Drug Test. Anal., 1 Mar 2017, 9 (3), 423-435. 1.4 MB. https://doi.org/10.1002/dta.2161 #6 GC,MS,NMR,other
Luethi, D; Kaeser, PJ; Brandt, SD; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of methylphenidate-based designer drugs Neuropharmacology, 15 May 2018, 134 (A), 133-140. 987 kB. https://doi.org/10.1016/j.neuropharm.2017.08.020
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #52
Brandt, SD; Kavanagh, PV. Addressing the challenges in forensic drug chemistry Drug Test. Anal., 1 Mar 2017, 9 (3), 342-346. 120 kB. https://doi.org/10.1002/dta.2169
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Piperidines Ethylnaphthidate
Carlier, J; Giorgetti, R; Varì, MR; Pirani, F; Ricci, G; Busardò, FP. Use of cognitive enhancers: methylphenidate and analogs Eur. Rev. Med. Pharmacol. Sci., 1 Jan 2019, 23 (1), 3–15. 676 kB. https://doi.org/10.26355/eurrev_201901_16741 #HDEP-2
Kobayashi, M; Okamoto, K; Otake, H; Ando, T. Identification of structural analogs of methylphenidate by GC/MS JCCL, 1 Oct 2017, (57), 75–83. 19.0 MB. #Ethylnaphthidate Japanese, English abstract GC,MS